Therapeutic interventions in parkinsonism: Corticobasal degeneration

Luca Marsili, Antonio Suppa, Alfredo Berardelli, Carlo Colosimo

Research output: Contribution to journalArticlepeer-review


Corticobasal degeneration (CBD) is a progressive neurodegenerative disorder resulting from pathological accumulation of tau protein and is included in the spectrum of Atypical Parkinsonism. The typical clinical phenotype of CBD is characterized by the Corticobasal syndrome (CBS). In recent years it has become clear that the clinical picture of CBS may be caused by different pathological conditions, resulting in frequent misdiagnosis.CBD has high morbidity and poor prognosis with no effective therapies. In this review, we will discuss the symptomatic treatment, the palliative care and the disease modifying strategies currently in use. Symptomatic treatment in patients with CBD may sometimes be useful for improving motor (parkinsonism, dystonia and myoclonus) and non-motor (cognitive-behavioral) symptoms, but the effects are often unsatisfactory. In addition, non-pharmacological strategies and palliative care are useful integrating components of the multidisciplinary therapeutic approach for patients with CBD. Despite many efforts, a disease-modifying treatment is still unavailable for CBD.

Original languageEnglish
Pages (from-to)S96-S100
JournalParkinsonism and Related Disorders
Publication statusPublished - Jan 1 2016


  • Corticobasal degeneration
  • Corticobasal syndrome
  • Dementia
  • Dopaminergic therapy
  • Parkinsonism

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Therapeutic interventions in parkinsonism: Corticobasal degeneration'. Together they form a unique fingerprint.

Cite this